Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for fertility preservation in women receiving radioiodine for papillary thyroid cancer
2024-518352-23-00Phase 3Authorised
- Sponsor
- Medical University of Białystok
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in papillary thyroid cancer (PTC) comparing Metformin arm with Placebo arm (2 arms). Primary endpoint: Effect of metformin on ovarian reserve and fertility markers. Planned start Nov 2022; status: authorised.
02
Drugs
metformin
03
Conditions
papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on 2024-518352-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518352-23-00.